Cell growth inhibition induced by BRAFi alone (vemurafenib) or in combination with MEKi (trametinib) was abrogated when 1205Lu melanoma cells were cultured on top of fibroblast‐derived ECMs, in sharp contrast to standard cell culture conditions where cells were plated either on plastic or on purified collagen 1 (Coll‐1) (Figs 2C and D, and EV1A). This evidence concerns the gene SEMA3A and melanoma.